MARKET WIREYahoo Finance UK • 1d ago
AngioDynamics, Inc. (ANGO) stock price, news, quote and historyYahoo Finance UK report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
Why ANGO Stock slipped -1.92% Today — RQD Quant Desk Flash
$11.76 -1.92% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $11.70
AngioDynamics Inc. (ANGO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $504.2M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on ANGO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is ANGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, AngioDynamics Inc. (NASDAQ: ANGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $11.76 (-1.92% 1D, market cap $504.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ANGO ranks #565 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does ANGO compare to SENS and SGHT in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), ANGO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 54.6%, and ROIC of -23.4%. By comparison, SENS (Senseonics Holdings Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $502.8M) and SGHT (Sight Sciences Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M). Among the 5-stock peer group, TCMD leads on earnings multiple (28.9x) while TCMD leads on capital efficiency (17.1% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for ANGO?
▼
Per ANGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001275187), AngioDynamics Inc. generated $320.2M in revenue (+9.5% YoY), -$36.7M in net income, and $508.0K in free cash flow against $269.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $11.70 (-0.54%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (36/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.3% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-9.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANGO)Realized 20D OHLCV Swing Band: ±11.6%
Deterministic 5-Pillar Attribution (36/100 Composite)
🔍 WHY ANGO SCORES 36/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+10/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 0.2% FCF Margin ($508.0K FCF) & 54.6% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (28% of score)
Altman Z-Score 2.12 (WATCH ZONE (1.8–3.0)) • Piotroski F-Score 6/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$10.90+8.3% Next Q
28
Q2 (-2Q)Grade E$11.81+3.8% Next Q
31
Q3 (-1Q)Grade E$12.26-4.1% Next Q
33
CurrentGrade D-$11.76-8.3% Hist 90D α
36
Trajectory: E (28) → D- (36)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ANGO Turnaround Squeeze
While ANGO currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($14.04) and Max Pain ($12.35) forces dealer call-delta covering toward $17.10.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANGO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ANGO Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ANGO Stock slipped -1.92% Today — RQD Quant Desk Flash
AngioDynamics Inc. (ANGO) slipped -1.92% to $11.76, trading at 34% of its 52-week range ($9.39 – $16.29). Stretched risk/reward at current multiples (-23% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 34% of its 52-week range ($9.39 – $16.29) with RSI-14 at 40.8 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.6% around $11.76 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 54.6% gross margin and $508000 annual free cash flow.
Live ANGO Headlines & Catalysts
MARKET WIREThe Motley Fool • 1d ago
Why AngioDynamics Crashed TodayThe Motley Fool report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo Finance • 1d ago
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
AngioDynamics, Inc. 2027 Q1 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2026-10-08Seeking Alpha report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSimply Wall St • 1d ago
AngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech ProgressSimply Wall St report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com • 1d ago
Canaccord reiterates AngioDynamics stock rating on growth platformsInvesting.com report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGuruFocus • 1d ago
AngioDynamics (ANGO) Prepares for Earnings Amid Mixed Signals on Valuation and Insider ActivityGuruFocus report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A pancreatic cancer study linked an electrical-pulse approach to 28 months’ median survival versus 15.Stock Titan report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Monday's Pre-Market SessionGainers Inovio Pharmaceuticals (NASDAQ:INO) shares increased by 232.0% to $2.0 during Monday's pre-market session. The company's market cap stands at $62.2 million. AngioDynamics (NASDAQ:ANGO) shares increased
MARKET WIREYahoo • 5d ago
AngioDynamics to Participate in Upcoming Investor ConferencesLATHAM, N.Y., October 29, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatmen
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANGO)
- ✓Walkthrough of ANGO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ANGO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +7.10%📐 HORIZONTAL RANGE
2026-11-03O $12.35H $12.35L $11.76C $11.76VOL 475.8K
RES: $17.74SUP: $10.44SMA50: $14.04SMA200: $12.49
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ANGO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +9.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on ANGO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ANGO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANGO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANGO)
Health Care Rank #565 of 1015
⚔️ SENS vs ANGO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ANGO vs. SENS, SGHT, DCTH, TCMD)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, AngioDynamics Inc. (ANGO) ranks #565 by composite RQD confidence (36/100, grade D-) and #440 by equity capitalization ($504.2M). Within this direct 5-issuer industry benchmark cohort, TCMD leads on earnings valuation at 28.9x trailing P/E, while TCMD leads on capital efficiency and profitability with 17.1% ROIC and 75.9% gross margin. TCMD currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with ANGO at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ANGO
ACTIVE
AngioDynamics Inc. | D- | 36/100 | — | 54.6% | -23.4% | -1.92% | $504.2M | Benchmark Subject |
| SENS Senseonics Holdings Inc. | D- | 40/100 | — | 44.7% | -35.0% | -5.57% | $502.8M | /sens-vs-ango → |
| SGHT Sight Sciences Inc. | D- | 39/100 | — | 86.2% | -35.0% | -1.82% | $513.4M | /sght-vs-ango → |
| DCTH Delcath Systems Inc. | C- | 59/100 | — | 86.2% | 0.8% | +1.78% | $487.2M | /dcth-vs-ango → |
| TCMD Tactile Systems Technology Inc. | C+ | 67/100 | 28.9x | 75.9% | 17.1% | -0.74% | $521.9M | /tcmd-vs-ango → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0001275187 ↗In its most recent audited fiscal period (FY2025, filed 2026-05-31), AngioDynamics Inc. (ANGO) reported GAAP revenue of $320.2M (+9.5% vs. FY2024 revenue of $292.5M , and +5.4% cumulative change since FY2023) , GAAP net income of -$36.7M, operating cash flow of $3.1M, and free cash flow of $508.0K (+103.5% YoY). On the balance sheet, ANGO closed FY2025 with $269.7M in total assets against $0 in total debt (Altman Z-Score: 2.12, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-05-31 | $320.2M | -$36.7M | $3.1M | $508.0K | $269.7M | — |
| FY2024 (FY) | 2025-05-31 | $292.5M | -$34.0M | -$10.1M | -$14.6M | $291.6M | — |
| FY2023 (FY) | 2024-05-31 | $303.9M | -$184.3M | -$28.2M | -$28.2M | — | — |
3. ANGO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ANGO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, AngioDynamics Inc. (NASDAQ: ANGO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $11.76 (-1.92% 1D, market cap $504.2M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ANGO ranks #565 in composite RQD confidence.
How does ANGO compare to SENS and SGHT in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), ANGO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 54.6%, and ROIC of -23.4%. By comparison, SENS (Senseonics Holdings Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $502.8M) and SGHT (Sight Sciences Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $513.4M). Among the 5-stock peer group, TCMD leads on earnings multiple (28.9x) while TCMD leads on capital efficiency (17.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ANGO?
Per ANGO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0001275187), AngioDynamics Inc. generated $320.2M in revenue (+9.5% YoY), -$36.7M in net income, and $508.0K in free cash flow against $269.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ANGO trading relative to its 50-day, 200-day, and 52-week technical levels?
ANGO last traded at $11.76 (-1.92% on volume of 456,653 shares), positioning the stock -16.24% below its 50-day simple moving average ($14.04) and -5.84% below its 200-day simple moving average ($12.49). Across its 52-week range of $9.39 to $16.29, ANGO sits at the 34.3% percentile with a 14-day RSI of 40.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.6% ($10.40 to $13.12).
ROARABLE RATING BRIEF • RQD 36/100 (D-)
✓ SEC XBRL & RQD VERIFIED
ANGO — AngioDynamics Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-05-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
AngioDynamics Inc. (ANGO) earns a live Roarable RQD composite score of 36/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $11.76 (-1.92% 1D, market capitalization $504.2M).
- Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of -23.4%, gross margin of 54.6%, operating margin of -12.5%, and free cash flow yield of 0.10%.
- Whale 13F & Options Flow (5/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.12, Piotroski F-Score of 6/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
AngioDynamics Inc. (ANGO) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry..5B. Per the market data, gross margin is 54.6%, indicating that the company retains a substantial share of revenue after direct costs. — for product lines, customer segments, or specific revenue-generation mechanics beyond the reported revenue figures.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-05-31), AngioDynamics Inc. (ANGO) reported $320.2M in annual revenue (up from $292.5M in FY2024, +9.5% YoY) and -$36.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($303.9M revenue, -$184.3M net income) through FY2025, ANGO scaled operating cash flow to $3.1M and free cash flow to $508.0K, backed by $269.7M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D- • RQD 36/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 0.10% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $9.39 – $16.29 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -12.5% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
No upstream or downstream dependencies, butterfly links, or proprietary signals are recorded. Sector: Health Care; industry: Medical/Dental Instruments. — for sector correlations or 2nd-order bottlenecks. Investors should note that the absence of mapped links is itself a data gap rather than evidence of independence.
- Key Question #1: Can ANGO sustain or expand its -12.5% operating margin and -23.4% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $320.2M and free cash flow of $508.0K, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is ANGO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
ANGO Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for AngioDynamics Inc. (ANGO) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 1d ago
AngioDynamics, Inc. (ANGO) stock price, news, quote and history Yahoo Finance UK report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 1d ago
Why AngioDynamics Crashed Today The Motley Fool report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 1d ago
AngioDynamics (ANGO) Reports Q1 Loss, Lags Revenue Estimates Yahoo Finance report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
AngioDynamics, Inc. 2027 Q1 - Results - Earnings Call Presentation (NASDAQ:ANGO) 2026-10-08 Seeking Alpha report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Simply Wall St • 1d ago
AngioDynamics (ANGO) Stock Price Sinks As Losses Cloud Med Tech Progress Simply Wall St report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com • 1d ago
Canaccord reiterates AngioDynamics stock rating on growth platforms Investing.com report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GuruFocus • 1d ago
AngioDynamics (ANGO) Prepares for Earnings Amid Mixed Signals on Valuation and Insider Activity GuruFocus report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A pancreatic cancer study linked an electrical-pulse approach to 28 months’ median survival versus 15. Stock Titan report covering AngioDynamics Inc. (ANGO) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
ANGO Bull vs. Bear Conversation Board — What's Your Call at $11.76?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANGO 🐻 33% BEARISH CONVICTION
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH
🎯 Target: $14.15 (+18.0%)
📌 Pinned Debate Revenue grew from $292.5M in FY 2024 to $320.2M in FY 2025 and the company posted a 54.6% gross margin.
Here is why I am bullish on ANGO here at $11.99: Revenue grew from $292.5M in FY 2024 to $320.2M in FY 2025 and the company posted a 54.6% gross margin.. Compare ANGO's -12.5% operating margin and -23.4% ROIC against the rest of Medical/Dental Instruments. As long as cash conversion holds up, dips toward $11.39 are getting bought.
EarningsSniper 🐂 BULL
Both sides have a point here — ANGO's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $9.23 (-23.0%)
Spot @ $11.99 ROIC of -23.4% and a 0.1% FCF yield indicate the business is not currently generating returns on invested capital.
ROIC of -23.4% and a 0.1% FCF yield indicate the business is not currently generating returns on invested capital.. Look at the math on ANGO: paying current EV/EBITDA multiples for -23.4% ROIC and -12.5% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $10.55 before getting long.